STOCK TITAN

MACROGENICS (MGNX) SEC Filings, Jun-Aug 2026

MGNX NASDAQ

MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.

Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.

Rhea-AI Summary

MacroGenics, Inc. reported second quarter 2026 results and a major strategic shift to a fully outsourced manufacturing model. The company completed the sale of its GMP drug substance manufacturing operations to Bora for a base purchase price of $122.5 million, receiving $119.6 million in cash at closing and reducing its workforce toward approximately 140 employees while entering a long-term supply agreement with Bora.

Pro forma cash, cash equivalents and marketable securities totaled $327 million as of June 30, 2026, supporting a stated cash runway through 2028. Quarterly revenue rose to $32.8 million, mainly from a $24.5 million Sanofi milestone, and net income was $19.5 million versus a prior-year loss, driven by $89.2 million income from discontinued operations and partly offset by a $52.8 million non-cash loss on extinguishment of a ZYNYZ royalty monetization liability. The pipeline advanced with Phase 1 progress for MGC026, ongoing studies for MGC028 and lorigerlimab, IND clearance for MGC030, and nomination of preclinical TCE MGD032, while the company remains eligible for up to approximately $2.4 billion in future milestones from partners.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
current report
-
Rhea-AI Summary

MacroGenics, Inc. (MGNX) reports a proposed sale by Jay Siegel, a former director, of 34,916 common shares, with an aggregate market value of $130,935. The notice lists August 3, 2026 as the approximate sale date and Merrill Lynch as the broker.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
other
-
Rhea-AI Summary

Bank of America Corporation filed an amended Schedule 13G reporting beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock. This represents 4.0% of the class, based on 63,563,123 shares outstanding as of May 8, 2026, from MacroGenics’ May 13, 2026 Form 10-Q.

Bank of America reports no sole voting or dispositive power and shared voting and dispositive power over all 2,556,475 shares, held through wholly owned subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and BofA Securities Europe SA. The filing confirms ownership of 5 percent or less of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
ownership
Rhea-AI Summary

BlackRock, Inc. reports beneficial ownership of 4,503,913 shares of MACROGENICS INC common stock on a Schedule 13G, representing 7.1% of the class as of June 30, 2026. This stake is held by certain BlackRock business units under SEC Release No. 34-39538.

BlackRock has sole voting power over 4,447,312 shares and sole dispositive power over 4,503,913 shares, with no shared voting or dispositive power. Various underlying clients may receive dividends or sale proceeds, but no individual client holds more than five percent of MacroGenics’ outstanding common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
ownership
-
Rhea-AI Summary

MacroGenics, Inc. reported an update on its ongoing Phase 1 study of MGC026, a B7-H3–directed antibody-drug conjugate for advanced solid tumors. Dose escalation from 1 mg/kg to 9 mg/kg q3W has been completed, and a 7.5 mg/kg q3W dose is being evaluated in four tumor-specific cohorts, including squamous cell carcinoma of the head and neck (SCCHN), endometrial cancer, melanoma and soft tissue sarcoma.

The SCCHN cohort, designed under Simon’s two-stage design with a planned 40-patient enrollment, has met the pre-specified Stage 1 response threshold and is now enrolling Stage 2. As of July 8, 2026, 74 patients had been enrolled across dose escalation and cohort expansion. No cases of interstitial lung disease or ocular toxicity had been reported, and evidence of anti-tumor activity was observed in several indications. MacroGenics plans to present dose-escalation and preliminary cohort data at the ESMO 2026 Congress in Madrid, including a poster on MGC026 on October 23, 2026 and a separate poster on lorigerlimab in advanced gynecologic cancers on October 26, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.73%
Tags
current report
-
Rhea-AI Summary

MacroGenics, Inc. received an amended Schedule 13G indicating that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander collectively report beneficial ownership of 2,374,296 shares of MacroGenics common stock. This represents 3.7% of the outstanding common stock.

The reporting persons disclose no sole voting or dispositive power and shared voting and shared dispositive power over 2,374,296 shares. They state that the securities are held by entities subject to their voting control or investment discretion and note that the filing should not itself be construed as an admission of beneficial ownership. They also confirm that they now own 5% or less of this class of securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.09%
Tags
ownership
Rhea-AI Summary

MacroGenics, Inc. former officer Thomas Spitznagel reported a proposed sale of 17,000 common shares, with an aggregate market value of $75,529 and an approximate sale date of July 13, 2026. The shares are listed as acquired from the issuer through stock plan activity on July 13, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
other
-
Rhea-AI Summary

MacroGenics, Inc. reported that board member Karen Ferrante, M.D. has decided to resign from its board of directors. She notified the board on July 1, 2026, with her resignation effective September 1, 2026. The company states that her decision is for personal reasons and not due to any disagreement related to operations, policies, or practices. MacroGenics publicly thanked Dr. Ferrante for her contributions to the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
current report
-
Rhea-AI Summary

MacroGenics, Inc. completed the sale of its GMP drug substance manufacturing and CDMO operations in Maryland to Bora Pharmaceuticals and Bora Biologics for $122.5 million in cash, subject to customary post-closing adjustments. Net cash proceeds recognized in the pro forma balance sheet are $110.7 million after working capital adjustments and estimated $8.0 million of transaction costs.

The purchaser assumed responsibility for the CDMO operations, including the Rockville manufacturing site and Frederick warehouse, and hired approximately 140 former MacroGenics employees. MacroGenics and Bora also entered into a supply agreement under which Bora will provide process development and drug substance production for MacroGenics’ pipeline.

On a pro forma basis for the year ended December 31, 2025, total revenue excluding the divested contract manufacturing business is $96.9 million, and net income is $46.3 million, compared with a historical net loss of $74.6 million. The pro forma gain on derecognition of the purchased assets is $109.7 million on January 1, 2025 and $106.1 million on March 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
current report
Rhea-AI Summary

MacroGenics, Inc. reported a Schedule 13G showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander have shared voting and dispositive power over 3,435,504 shares of MacroGenics common stock, equal to 5.4% of the class as shown with a 06/01/2026 time anchor. The filing is a joint filing and includes a Joint Filing Agreement dated June 4, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
ownership

FAQ

How many MACROGENICS (MGNX) SEC filings are available on StockTitan?

StockTitan tracks 84 SEC filings for MACROGENICS (MGNX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for MACROGENICS (MGNX)?

The most recent SEC filing for MACROGENICS (MGNX) was filed on November 16, 2026.